yvandenbroek
/
sprookjes
/
Login
Register
TriplyDB
sprookjes
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
2
Q46483294-8C181216-6DB5-41E3-ABED-BAABEC488021
Q46483294-8C181216-6DB5-41E3-ABED-BAABEC488021
BestRank
Statement
http://www.wikidata.org/entity/statement/Q46483294-8C181216-6DB5-41E3-ABED-BAABEC488021
A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors.
P2860
Q46483294-8C181216-6DB5-41E3-ABED-BAABEC488021
BestRank
Statement
http://www.wikidata.org/entity/statement/Q46483294-8C181216-6DB5-41E3-ABED-BAABEC488021
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
560c0ed5ad1b6cd696b531671ff64b36ad365f20
P2860
Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor.